AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A method of delaying development of a ~~symptom of~~ lesion associated with papillomavirus infection in a mammal who has been exposed to papillomavirus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said mammal, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3', wherein the mammal is a human, wherein a papillomavirus antigen is not administered in conjunction with administration of said composition, wherein said composition is administered at a papillomavirus-associated lesion, and wherein said composition is administered in an amount sufficient to delay development of a ~~symptom of~~ lesion associated with papillomavirus infection.

2. (original): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.

3. (original): The method of claim 2, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCG-3', and 5'-GACGTTCG-3'.

4. (original): The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).

5. (canceled)

6. (previously presented): The method of claim 1, wherein said lesion is a wart, a papilloma, a condyloma, a neoplasia or a dysplasia.

7-8. (canceled)

9. (currently amended): A method of reducing severity of a ~~symptom of~~ lesion associated with papillomavirus infection in a mammal infected with papillomavirus, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said mammal, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3', wherein the mammal is a human, wherein a papillomavirus antigen is not administered in conjunction with administration of said composition, wherein said composition is administered at a papillomavirus-associated lesion, and wherein said composition is administered in an amount sufficient to reduce severity of a ~~symptom of~~ lesion associated with papillomavirus infection.

10. (original): The method of claim 9, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.

11. (original): The method of claim 10, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCG-3' and 5'-GACGTTCG-3'.

12. (original): The method of claim 9, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).

13. (canceled)

14 (previously presented): The method of claim 9, wherein said lesion is a wart, a papilloma, a condyloma, a neoplasia or a dysplasia.

15-22. (canceled)

23. (previously presented): The method of claim 1, wherein the polynucleotide comprises a phosphate backbone modification.

24. (previously presented): The method of claim 23, wherein the phosphate backbone modification is a phosphorothioate.

25. (previously presented): The method of claim 9, wherein the polynucleotide comprises a phosphate backbone modification.

26. (previously presented): The method of claim 25, wherein the phosphate backbone modification is a phosphorothioate.